MABPLEX USA, INC provides integrated oversight to synchronize complex conjugation cycles for dual-payload ADCs.
Public source
Publisher name
Public post
Dual-payload ADCs (dpADC) have emerged as a critical strategy for overcoming tumor heterogeneity. AACR 2026 highlights that nearly 90% of reported dpADCs utilize Topo1i-…
Company
MABPLEX USA, INC
MabPlex, your trusted CDMO partner for mAbs and ADC
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 2–10 employees
About MABPLEX USA, INC
MABPLEX USA, INC offers our partners contract services from DNA to finished drug product.
See moreLatest activity
Latest activity from MABPLEX USA, INC
12 signals
Products & Services
MABPLEX USA, INC scientists specialize in adapting conjugation chemistries for non-traditional payloads.
Products & Services
MABPLEX USA, INC provides specialized solubility protocols for non-cytotoxic payloads.
Products & Services
MABPLEX USA, INC provides comprehensive stability profiles for novel conjugates.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
Guidant BioTherapeutics
Guidant BioTherapeutics' ADC platform conjugation side attaches two different toxin payloads at a controlled DAR of 2 to 4 on a patented docking peptide joined by a chemical linker to the targeting component.
Products & Services
WuXi XDC
WuXi XDC developed WuXiDAR1™, a conjugation tool designed to simplify antibody-oligonucleotide conjugate development and amplify research success.
Products & Services
Abzena
Abzena runs head-to-head comparative studies across conjugation chemistry, release mechanism, and OAR early in development.
Products & Services
Fortis Life Sciences
Fortis Life Sciences works on custom conjugate development for antibodies, proteins, nucleic acids, peptides, and other biomolecules at nanoComposix, from early feasibility through scale-up and manufacturing.
Products & Services
Kyinno Biotechnology, Inc.